Janssen’s Invokana: New analysis of the CREDENCE study

Janssen has announced results from a new analysis of its Phase 3 CREDENCE, which demonstrated that Invokana (canagliflozin), its flagship sodium glucose transport-2 inhibitor (SGLT-2I), was able to consistently reduce the risk of renal and cardiovascular (CV) events in patients with varying levels of kidney function.